Tofacitinib for the treatment of alopecia areata and variants in adolescents

Journal of the American Academy of Dermatology

Volumn 76, Issue 1, 2017, Pages 29-32

  Craiglow, Brittany G ^a   Liu, Lucy Y ^a   King, Brett A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adolescent; alopecia areata; Janus kinase; tofacitinib

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; SQUARIC ACID; SQUARIC ACID DIBUTYLESTER; TOFACITINIB; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADOLESCENT; ADVERSE OUTCOME; ALOPECIA AREATA; ALOPECIA TOTALIS; ALOPECIA UNIVERSALIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; EVENING DOSAGE; FEMALE; HAIR GROWTH; HEADACHE; HUMAN; LABORATORY TEST; MALE; MEDICAL RECORD; MORNING DOSAGE; PERSONAL EXPERIENCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEVERITY OF ALOPECIA TOOL; SIDE EFFECT; SKIN DISEASE ASSESSMENT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ALOPECIA; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ALOPECIA; ALOPECIA AREATA; FEMALE; HUMANS; MALE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85005848060     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.09.006     Document Type: Article

References (14)

1. 1 Xing, L., Dai, Z., Jabbari, A., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20 (2014), 1043–1049.
2. 2 Craiglow, B.G., King, B.A., Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134 (2014), 2988–2990.
3. 3 Gupta, A.K., Carviel, J.L., Abramovits, W., Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol 30 (2016), 1373–1378.
4. 4 Jabbari, A., Nguyen, N., Cerise, J.E., et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol 25 (2016), 642–643.
5. 5 Pieri, L., Guglielmelli, P., Vannucchi, A.M., Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol 90 (2015), 82–83.
6. 6 Craiglow, B.G., Tavares, D., King, B.A., Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol 152 (2016), 490–491.
7. 7 Jabbari, A., Dai, Z., Xing, L., et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2 (2015), 351–355.
8. 8 Crispin, M., Ko, J., Craiglow, B.G., et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1(15), 2016, e89776.
9. 9 Liu, L.Y., Craiglow, B.G., Dai, F., King, B.A., Tofacitinib for the treatment of severe alopecia areata and variants: Results in 90 patients. J Am Acad Dermatol 76 (2017), 22–28.
10. 10 Olsen, E., Hordinsky, M., McDonald-Hull, S., et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 40 (1999), 242–246.
11. 11 Liu, L.Y., King, B.A., Craiglow, B.G., Health-related quality of life (HRQoL) among patients with alopecia areata: a systematic review. J Am Acad Dermatol 75:4 (2016), 806–812.
12. 12 Colon, E.A., Popkin, M.K., Callies, A.L., et al. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 32 (1991), 245–251.
13. 13 Kyriakis, K.P., Paltatzidou, K., Kosma, E., Sofouri, E., Tadros, A., Rachioti, E., Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol 23 (2009), 572–573.
14. 14 Montealegre, G., Reinhardt, A., Brogan, P., et al. Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE). Pediatr Rheumatol Online J, 13, 2015 S1-O31.